Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or North Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to North Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. North Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Julia Schaefer-cutillo (NPI 1912911389)

Field	Value
Entity Type	Individual
Organization	Julia Schaefer-cutillo
Address	1503b N Road St
City	Elizabeth City
State	NC
ZIP	27909
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 28, 2006

Payer Source	Total Paid
Medicare	$4M
Medicaid	$0

Key Findings

This provider is a hematology & oncology physician with a long Medicare presence, enumerated since 2006-07-28 (about 20 years). That tenure indicates established clinical operations and a sustained Medicare billing relationship rather than a recent entrant in the market. The profile supports interpretation of consistent oncology-focused outpatient activity over an extended period.

Medicare is the overwhelmingly dominant payer for this provider: lifetime Medicare revenue is $4M while there is no Medicaid billing on file, making the provider effectively single-payer (Medicare) in our dataset. Analysts should treat Medicaid as absent when modeling payer mix or network access for this provider.

Revenue concentration is highly focused: the top three Medicare codes together account for 79.7% of total Medicare revenue, indicating that a small set of drug administrations drives most of the practice’s Medicare income. This concentration suggests the business is centered on high-cost oncology infusions rather than a broad mix of office-based E/M services.

The provider is a national outlier on some oncology drug codes. J9271 (pembrolizumab) generated $2.4M (61.9% of Medicare revenue) and the provider ranks #13 of 1841 nationally (99th percentile), labeled an extreme outlier — signaling exceptionally high volume of pembrolizumab billing compared with peers. Similarly, 96413 (chemotherapy administration) is an extreme outlier by rank (#113 of 7514, 99th percentile), reinforcing that high-volume infusion therapy is core to the practice.

Other oncology-supportive drugs also appear at elevated volumes: J9299 (nivolumab) produced $385.9K (10.1% of Medicare revenue) with a mid-level national rank (222 of 505, 56th percentile), while J0897 (denosumab) accounted for $293.8K (7.7% of revenue) and ranks #447 of 10057 (96th percentile), described as notably above typical national volume. These code-level patterns together indicate a service line mix emphasizing immunotherapy and supportive bone-targeted agents in addition to direct chemotherapy.

The practice reports substantial procedural and visit-level activity but these are a small share of revenue compared with drug billing: E/M codes 99214 and 99213 together account for modest revenue ($92.5K and $47.1K respectively) and rank in high percentiles nationally, implying a steady outpatient follow-up and management workload that complements infusion services. Infusion-related administration add-on and supply codes (96375, 96417, G0498) also appear above typical volumes, consistent with an infusion-centric clinic workflow.

Several codes are statistical extremes for volume and should shape competitive assessments: high ranks labeled “extreme outlier” or “notably above typical” for J9271, 96413, 96375, and 96372 indicate this provider is a major national-volume administrator of certain oncology drugs and infusion services, making them a significant node in the pembrolizumab/nivolumab treatment supply chain. By contrast, some drug codes (e.g., J0885, J9217) sit at typical or lower percentiles, showing the provider’s dominance is concentrated in specific biologics rather than uniformly across all oncology medications.

For payer or network negotiation and capacity-planning, the combination of extreme pembrolizumab revenue ($2.4M) and the overall $4M Medicare lifetime intake implies this clinician or site is heavily dependent on a few high-cost biologics; any changes in coverage, reimbursement, or utilization of those specific agents could materially impact practice revenue. Given no Medicaid activity, capacity assumptions for Medicaid beneficiaries should be treated as negligible unless external data indicates otherwise.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

90 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	55,000	$40	$2.4M
J9299	Injection, nivolumab, 1 mg	16,080	$20	$385.9K
J0897	Injection, denosumab, 1 mg	16,320	$20	$293.8K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	60,240	$1	$120.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,020	$90	$92.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	910	$100	$86.7K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	960	$80	$77.8K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	700	$100	$66.5K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	770	$60	$47.1K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	3,040	$10	$30.4K

Showing 1–10 of 90

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 90 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. North Carolina Distribution

Julia Schaefer-cutillo — 16 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — North Carolina

Full comparison — all codes billed, vs. state median

90 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	30	9,600	$40	$528.3K
J9299	3	10	10,800	$20	$295.8K
88185	4	10	1,270	$20	$216.1K
J0897	8	430	2,100	$20	$63.9K
J2506	1	10	850	$80	$61K
82784	6	30	210	$10	$50.3K
83520	4	10	290	$20	$48.3K
88184	4	10	60	$50	$29.9K
Q5122	1	10	260	$90	$28.8K
86334	16	40	140	$20	$25.4K

Showing 1–10 of 90

Related Providers

Other providers that share a Tax Identification Number (TIN) with Julia Schaefer-cutillo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Edward Bennett	NY	Internal Medicine Physician	$152.7K	$6.7M
Virginia Oncology Associates	VA	Hematology & Oncology Physician	$0	$6.2M
Maryland Oncology Hematology P.A.	MD	Hematology & Oncology Physician	$0	$4.6M
Victor Archie	VA	Radiation Oncology Physician	$4M	$0
Mark Fleming	VA	Hematology & Oncology Physician	$3.9M	$0
Eric Shakin	NY	Ophthalmology Physician	$3.3M	$291.7K
Thomas Alberico	VA	Hematology & Oncology Physician	$3.5M	$0
Lynda Piboon	NY	Obstetrics & Gynecology Physician	$62.2K	$3.1M
David Kobulnicky	VA	Hematology & Oncology Physician	$3M	$0
Celesteann Bremer	VA	Hematology & Oncology Physician	$2.8M	$0

Nearby Providers

Other providers in the same ZIP code as Julia Schaefer-cutillo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sentara Albemarle Regional Medical Center	NC	General Acute Care Hospital	$0	$13.8M
Cmg Of North Carolina, Inc.	NC	Pediatrics Physician	$0	$9.1M
Benjamin House, Inc.	NC	Developmentally Disabled Services Day Training Agency	$0	$7.1M
The Brooks Senior Living LLC	NC	Assisted Living Facility	$0	$7M
County Of Pasquotank Office Of The Treasurer	NC	Paramedic	$1.2M	$1.7M
Lindsey White	NC	Cardiovascular Disease Physician	$820.2K	$0
Jitendra Swarup	NC	Ophthalmology Physician	$702.6K	$0
Alan Maniet	NC	Cardiovascular Disease Physician	$556.2K	$0
Tejwant Chandi	NC	Internal Medicine Physician	$514.9K	$0
Sidney Sutton	NC	Family Medicine Physician	$315.4K	$0

Julia Schaefer-cutillo — Billing Profile & Reimbursement Data

Sign up for Julia Schaefer-cutillo — Billing Profile & Reimbursement Data policy alerts

Julia Schaefer-cutillo — Billing Profile & Reimbursement Data

Sign up for Julia Schaefer-cutillo — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References